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Hydrochlorothiazide (HCTZ) is used to manage hypertension
and heart failure; however, its side effects include mild
hypokalemia, metabolic abnormalities, and volume
depletion, which might have deleterious effects on renal and
endothelial function. We studied whether HCTZ cause renal
injury and/or altered vasoreactivity and if these changes are
hypokalemia-dependent. Rats were given a normal diet or a
diet moderately low in potassium (Kþ ) with or without HCTZ.
Animals fed either a low Kþ diet alone or HCTZ developed
mild hypokalemia. There was no significant difference in
systolic blood pressure in the different treatment groups.
All three groups with hypokalemia had mild proteinuria;
low Kþ -HCTZ rats had reduced creatinine clearance.
HCTZ-treated rats displayed hypomagnesemia,
hypertriglyceridemia, hyperglycemia, insulin resistance, and
hyperaldosteronism. No renal injury was observed in the
groups without HCTZ; however, increased kidney weight,
glomerular ischemia, medullary injury, and cortical oxidative
stress were seen with HCTZ treatment. Endothelium-
dependent vasorelaxation was reduced in all hypokalemic
groups and correlated with reduced serum Kþ , serum, and
urine nitric oxide. Our results show that HCTZ is associated
with greater renal injury for the same degree of hypokalemia
as the low Kþ diet, suggesting that factors such as chronic
ischemia and hyperaldosteronism due to volume depletion
may be responsible agents. We also found impaired
endothelium-dependent vasorelaxation was linked to mild
hypokalemia.
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Hydrochlorothiazide (HCTZ) and other thiazide diuretics
reduce morbidity and mortality in hypertensive subjects by
reducing the frequency of stroke and congestive heart
failure.1–3 However, thiazides do not protect against myo-
cardial infarction relative to that expected for the degree of
decrease in blood pressure1,4 and thiazides may also not
protect against progressive renal disease.5–7 Some studies
suggest HCTZ use may actually increase the risk for renal
progression in subjects with essential hypertension.7 Indeed,
HCTZ exacerbates renal injury in the spontaneously
hypertensive rat.8,9
One potential mechanism by which thiazides might cause
renal injury is via the induction of hypokalemia. Hypokale-
mia is a common clinical condition and occurs in 6.5–50% of
patients receiving diuretics.10–12 The relationship between
hypokalemia and thiazides is dose-dependent, with the
average reduction of serum potassium around
0.3–1.1 mEq l1.13–15 Studies in animals placed on severe
potassium restricted diets have shown the development of
hypokalemic nephropathy characterized by renal hypertro-
phy, renal tubular cell hyperplasia, tubular dilatation,
interstitial cell infiltration, and fibrosis that is greatest in
the outer medulla. This injury is mediated by both intrarenal
complement activation16 and intrarenal vasoconstriction
secondary to an increase in vasoconstrictors (endothelin
and angiotensin II) and a loss of vasodilators (nitric oxide
(NO), prostaglandins, and kallikrein).17 Increased vasocon-
striction with oxidative stress was also observed in the carotid
artery of animals fed a low Kþ diet (LK).18 In addition to
hypokalemia, HCTZ may induce hypomagnesemia, hyperur-
icemia, hyperlipidemia, and impaired glucose metabo-
lism6,19–22 that could also contribute to renal injury and
endothelial dysfunction. This has raised concern that HCTZ
may be a double-sided sword with both beneficial and
negative effects.
To date no study has attempted to distinguish the renal
effects of thiazides from those induced by mild hypokalemia.
Furthermore, to our knowledge, all previous studies examin-
ing the effect of potassium restriction on renal function and
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structure have utilized near complete potassium restriction,
which is not physiologic. Hence, we determined if thiazide
usage can induce renal injury and alter vasoreactivity and
compared this with equivalent hypokalemia induced by
moderate potassium restriction.
RESULTS
Serum Kþ , body weight, and urine volume
Rats fed on either a LK diet and/or HCTZ developed mild
hypokalemia. Serum Kþ fell by 10–15% within the first 2
weeks and reached 70–80% of control (normal Kþ diet
(NK)) levels by week 20 (Table 1). Serum Kþ was lowest in
the LKþHCTZ group but was similar in the LK and
NKþHCTZ groups (Table 1 and Figure 1a). Hypokalemia
was accompanied by increased serum bicarbonate (Table 1).
Body weight (BW) was lower in both the LK and
LKþHCTZ groups at week 2 (Table 1), but at killing, BW
was only lower in the LKþHCTZ group compared with the
others (Table 1 and Figure 1b). Nevertheless, the correlation
between BW and serum Kþ at week 20 was significant
(r¼ 0.49, P¼ 0.025).
Urine volumes were increased significantly in both groups
given HCTZ for the first 2 weeks but then were similar to the
NK group (Figure 1c). The LKþHCTZ group had greater
urine volume compared with the HCTZ group at day 3
(P¼ 0.03). LK rats also had a tendency toward higher urine
output during the first 2 weeks, although it was not
significant (P¼ 0.069 at day 3 and 0.057 at day 7 compared
with the NK group).
The metabolic effects of HCTZ, serum insulin, and insulin
resistance
Consistent with reports in humans, both HCTZ-treated
groups developed hypomagnesemia and hyperglycemia at
weeks 4 and 15 (Table 2). Serum glucose negatively correlated
with serum Kþ (r¼0.44, P¼ 0.044). Also, serum trigly-
cerides were higher in NKþHCTZ and LKþHCTZ rats
compared with the NK and LK rats at week 20, although this
did not reach significance in the latter (Po0.05 and 0.07,
respectively). Serum uric acid and cholesterol were not
different among groups. A tendency for higher hemoglobin
was observed in rats receiving thiazides (P¼ 0.07 vs NK
group and P¼ 0.05 vs LK group).
Table 1 | Effects of low K+ diet and HCTZ on body weight, kidney weight, serum K+, and renal function
Group 1 (NK) Group 2 (LK) Group 3 (NK+HCTZ) Group 4 (LK+HCTZ)
Body weight (g)
At baseline 16678.3 16677.2 16675.5 16675.7
At week 2 290713 252732y,h 291720 246723y,h
At week 20 641797 605761 6167106 506758*,f
Kidney weight (g) 1.5770.2 1.4370.2 1.7370.3 1.4670.2
Kidney weight/BW (g per100 g) 0.2570.01 0.2470.01 0.2870.02y,d 0.2970.03y,d
Serum K+ (mEq l1)
At week 2 4.770.2 4.170.1y 4.170.2y 3.970.2y,z,f
At week 20 4.670.1 3.670.2y 3.570.1y 3.270.1y,d,h
Serum bicarbonate at week 20 (mEq l1) 21.671.5 23.671.3* 23.471.0* 24.371.5y
BUN (mg dl1) 15.872.2 17.472.9 20.773.3* 21.873.9y,z
Serum Cr (mg dl1) 0.4870.04 0.570.07 0.5770.08 0.5570.08
Creatinine clearance (ml min1) 2.3670.3 2.2370.4 2.0470.4 1.7470.2y,z
Urinary protein/Cr (mg per mg Cr) 2.2270.8 3.3270.5* 3.6370.6y 3.6270.6y
BW, body weight; BUN, blood urea nitrogen; NK, normal K+ diet group; LK, low K+ diet group; K+HCTZ, normal K+ diet plus hydrochlorothiazide group; LK+HCTZ, low K+ diet
plus hydrochlorothiazide group.
*Po0.05, yPo0.01 vs group 1, zPo0.05, dPo0.01 vs group 2, fPo0.05, hPo0.01 vs group 3.
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Figure 1 | Effect of dietary potassium and HCTZ on (a) serum potassium, (b) BW and (c) urine volume. The LKþHCTZ rats had the
lowest serum Kþ and body weight, whereas the LK and NKþHCTZ groups had a similar degree of hypokalemia and body weight
recorded after 2 weeks. Urine volumes of the HCTZ-treated rats increased significantly in the first 2 weeks of treatment and a tendency in
the LK rats. Data expressed as mean7s.d. for serum Kþ and body weight and mean7s.e. for urine volume. D1–D3 represented as days 1
and 3, W1–W20 as week 1–20.
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Serum insulin. Serum insulin in rats receiving an LK had a
tendency to be lower compared with rats receiving an NK
(NK 256071010 vs LK 21647870, and NKþHCTZ 34097
949 vs LKþHCTZ 23247762 pg ml1, P¼ 0.076). Although
the LK and NKþHCTZ groups had similar serum Kþ levels,
serum insulin of the NKþHCTZ rats was significantly
higher (Table 2).
Quantitative insulin sensitivity check index. HCTZ-treated
rats demonstrated insulin resistance compared with non-
HCTZ receiving rats (NK vs NKþHCTZ, P¼ 0.031 and LK
vs LKþHCTZ, P¼ 0.079 and LK vs NKþHCTZ, P¼ 0.002,
Table 2).
Serum aldosterone
Compared with NK rats (270.5746.8 pg ml1), NKþHCTZ
rats had higher serum aldosterone levels (4437182.1 pg ml1,
Po0.05, Table 2). LK rats had lower serum aldosterone levels
(165.4735.9 pg ml1) compared with NK rats (Po0.01).
Muscular (intracellular) Kþ , Naþ , and Mgþ þ levels
The muscular Kþ content of LK, NKþHCTZ, and
LKþHCTZ rats were significantly lower compared with
NK rats, whereas the muscular Mgþ þ content adjusted for
muscular protein was lower in HCTZ-treated rats (Table 3).
All groups had similar Naþ content. There was significant
correlation between muscular Kþ and Mgþ þ (r¼ 0.78,
Po0.001).
Renal injury
Kidney weight adjusted for BW. Although absolute kidney
weights were not different, the kidney weight to body weight
(KW/BW) ratio was significantly increased in both the
NKþHCTZ and LKþHCTZ groups when compared with
NK and LK rats (Table 1).
Renal function. Serum blood urea nitrogen, creatinine,
creatinine clearance, and urinary protein excretion are shown
in Table 1. All three groups with hypokalemia (LK,
NKþHCTZ, and LKþHCTZ rats) had increased protein
excretion compared with NK rats. A tendency for higher
serum creatinine was observed in the NK+HCTZ rats
(P¼ 0.057 vs NK rats). Creatinine clearance was depressed
in the LKþHCTZ group compared with the NK group and
tended to be lower in the NKþHCTZ group.
Renal histology and immunohistochemistry. Neither glo-
merular hypertrophy (measured as total glomerular tuft area)
nor mesangial matrix area was different between the four
groups. No global or segmental glomerulosclerosis was
observed in any group. There was no significant structural
renal damage in NK and LK rats, whereas focal glomerular
injury—characterized by wrinkling and thickening of the
glomerular basement membrane, splitting of the Bowman
capsule, glomerular collapse, and periglomerular fibrosis
(Figure 2)—was revealed in both HCTZ-treated groups. This
pattern of glomerular change suggested glomerular ische-
mia23 or early changes of glomerular atrophy. Additionally,
Table 2 | Biochemical parameters and serum insulin and serum aldosterone levels
Group 1 (NK) Group 2 (LK) Group 3 (NK+HCTZ) Group 4 (LK+HCTZ)
Serum Mg++ (mEq l1) 2.170.26 2.070.1 1.670.1y,d 1.570.2y,d
Serum glucose (mg dl1) 161.7717.9 145.8716.2 202.7737.3*,d 193.7720.3*,d
Serum uric acid (mg dl1) 2.3870.5 2.2470.3 2.470.2 2.3670.4
Serum cholesterol (mg dl1) 97.5726.1 117.8730.2 100.0723.6 78.2711.0
Serum triglycerides (mg dl1) 139.2733.4 117.3740.9 228.8752.7*,d 189.8780.5
Hemoglobin (g dl1) 14.971.2 14.970.8 16.071.7 16.571.0
Serum insulin (pg ml1) 256071010 21647870 34097949z 23247762
QUICKI 0.17970.006 0.18370.005 0.17370.003*,d 0.17770.004
Serum aldosterone (pg ml1) 270.5746.8 165.4735.9y 443.07182.1*,d 297.9752.5d
LK, low K+ diet group; LK+HCTZ, low K+ diet plus hydrochlorothiazide group; NK, normal K+ diet group; NK+HCTZ, normal K+ diet plus hydrochlorothiazide group; QUICKI,
quantitative insulin sensitivity check index.
*Po0.05, yPo0.01 vs group 1, zPo0.05, dPo0.01 vs group 2.
Table 3 | Effects of low K+ diet and HCTZ on muscular K+, Na+, and Mg++ contents
Group 1 (NK) Group 2 (LK) Group 3 (NK+HCTZ) Group 4 (LK+HCTZ)
Muscular K+ content
mmol per g tissue 106.4715.4 89.7712.5* 88.778.9* 82.572.9y
mmol per mg protein 31.375.5 21.374.5* 20.177.8y 19.673.7y
Muscular Mg++ content
mmol per g tissue 12.370.4 11.971.6 11.570.9 11.770.4
mmol per mg protein 3.770.8 3.170.6 2.770.6* 2.870.5*
Muscular Na+ content
mmol per g tissue 29.177.3 30.075.2 28.973.0 28.973.4
mmol per mg protein 7.272.4 7.473.0 6.572.3 6.872.2
LK, low K+ diet group; NK, normal K+ diet group; NK+HCTZ, normal K+ diet plus hydrochlorothiazide group; LK+HCTZ, low K+ diet plus hydrochlorothiazide group.
*Po0.05, yPo0.01 vs group 1.
Kidney International (2007) 72, 1483–1492 1485
S Reungjui et al.: Thiazide induced renal injury o r i g i n a l a r t i c l e
renal tubulointerstitial injury, such as tubular dilatation, cast
formation, and interstitial cell infiltration, was also present in
both HCTZ-treated groups. Although the renal injury
induced by thiazides was subtle (less than 10% of area), it
was significant when compared with that of the NK and LK
groups (Table 4 and Figure 3a–d). Injury to the medulla was
also observed in rats receiving HCTZ, despite the fact that the
LK group had similar potassium levels as the NKþHCTZ
group. The LKþHCTZ group had more extensive renal
damage than the other groups.
Osteopontin expression was increased significantly in
LKþHCTZ rats within the outer stripe of outer medulla and
within the inner stripe of outer medulla (ISOM) of both
NKþHCTZ and LKþHCTZ groups (Table 4 and Figure
4a–d). Similarly, an increase in interstitial macrophage
infiltration in the outer medulla was observed in both
NKþHCTZ and LKþHCTZ groups (Table 4).
Renal tubular cell proliferation of collecting ducts and
medullary thick ascending limb (mTAL) was demonstrated
by positive proliferative cell nuclear antigen (PCNA) staining,
which was significantly higher in both NKþHCTZ and
LKþHCTZ groups compared with NK and LK groups
(Table 4 and Figure 5a–d).
Renal oxidative stress
We investigated 8-isoprostaglandin F2 alpha and intracellular
reduced glutathione as markers of oxidative stress (Table 5).
Cortical 8-isoprostaglandin F2 alpha was higher in both
groups receiving HCTZ. Intracellular reduced glutathione
was decreased in the LKþHCTZ group. Additionally,
intracellular reduced glutathione correlated positively with
renal NO within both cortex (r¼ 0.49, P¼ 0.025) and
medulla (r¼ 0.46, P¼ 0.038).
Endothelium-dependent vasorelaxation and NO
The percent relaxation of aortic rings in response to
acetylcholine was reduced in all three hypokalemic groups
compared with NK controls (Figure 6a). All three hypoka-
lemic groups also had significantly lower serum nitrite, urine
nitrate and nitrite levels (Table 6). Renal nitrate and nitrite
levels were lower in the cortex but not in the medulla in the
hypokalemic groups (Table 6). The decrease in serum nitrites
Figure 2 | Periodic acid-Schiff staining of the cortex of
HCTZ-treated rat. Focal glomerular injury characterized by wrinkling
and thickening of the glomerular basement membrane, with splitting
of Bowman’s capsule, glomerular collapse, and periglomerular
fibrosis (yellow arrow) was present in rats in both HCTZ-treated
groups. This pattern of glomerular change is consistent with
glomerular ischemia or early glomerular atrophy. Thickening of
peritubular basement membrane around the injured glomerulus was
also noted (black arrow). Original magnification  630.
Table 4 | Glomerular and tubulointerstitial injury in the HCTZ-treated rats
Group 1 (NK) Group 2 (LK) Group 3 (NK+HCTZ) Group 4 (LK+HCTZ)
Glomerular area (mm2) 20957218 20497266 21127262 19407151
Mesangial area (%)a 20.570.6 20.670.9 21.571.1 20.370.9
Cortical lesions (score 0–5)
Glomerular injury 0 0 0.6770.5*,z 0.8870.4y,d
Tubulointerstitial injury 0.270.3 0.1770.3 0.2270.3 0.6770.2*,z,f
Medullary lesions (score 0–5) 0 0 0.8370.4y,d 0.6770.5*,z
Osteopontin (%)
Cortex 0.2970.1 0.4370.3 0.6270.5 0.5570.3
OSOM 0.3070.2 0.5070.2 0.7770.6 0.6670.3*
ISOM 4.3370.8 4.5071.1 5.8571.3* 6.7571.4y,z
ED-1 (cells mm2)
OSOM 30.175.7 38.275.5 45.976.6y 57.675.7y,d,h
Junction of OSOM & ISOM 36.5715.7 39.176.1 52.3712.2 59.8717.7*,z
PCNA (cells mm2)
Cortex 9.171.5 11.373.0 46.178.9y,d 47.7714.5y,d
OSOM 13.973.0 13.472.0 55.9715.3y,d 63.2721.7*,z
ISOM 17.871.7 21.7711 63.4717.8y,z 81.5746.0*,z
ISOM, inner stripe of outer medulla; LK, low K+ diet group; LK+HCTZ, low K+ diet plus hydrochlorothiazide group; NK, normal K+ diet group; NK+HCTZ, normal K+ diet plus
hydrochlorothiazide group and OSOM; outer stripe of outer medulla.
*Po0.05, yPo0.01 vs group 1, zPo0.05, dPo0.01 vs group 2, fPo0.05, hPo0.01 vs group 3.
aPercentage of mesangial area within the glomerulus.
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correlated with the degree of hypokalemia and with the
degree of impaired vasorelaxation of the aortic rings (Table 7
and Figure 6b).
Systolic blood pressure
Blood pressure was not measured in the original cohort.
However, another set of animals was treated identically and
systolic blood pressure was measured at week 6. Tail cuff
blood pressures of the NK, LK, NKþHCTZ, and
LKþHCTZ groups were 13274.7, 13177.9, 12873.5, and
12678.5 mm Hg, respectively (P¼NS).
DISCUSSION
We compared the effects of mild hypokalemia induced by diet
with mild hypokalemia induced by the diuretic thiazide on
renal structure and function. The reason for this study was
three-fold. First, our group and others have previously shown
that marked potassium restriction (typical diets of 0.01% K)
can induce substantial renal injury (hypokalemic nephro-
pathy), but it remains unknown if milder dietary potassium
restriction can induce renal damage. Second, the most
common form of hypokalemia observed clinically is with
diuretic use, and this observation, coupled with reports that
thiazide diuretics might induce renal injury by themselves,
raised the question of whether thiazides would induce similar
or worse renal damage for the same degree of hypokalemia.
Finally, the most important reason to perform these studies is
that both diuretic usage and mild hypokalemia are common
in clinical practice and it is important to determine if these
processes can result in renal damage and whether they are
additive.
a b
dc
Figure 3 | Periodic acid-Schiff staining of the ISOM of (a) NK, (b)
LK, (c) NKþHCTZ, and (d) LKþHCTZ rats. The HCTZ-treated rats
had renal tubular dilatation and cast formation (yellow arrows) and
interstitial cell infiltration (black arrows). Original magnification
 200. ISOM, inner stripe of outer medulla; NK, normal Kþ diet
group; LK, low Kþ diet group; NKþHCTZ, normal Kþ diet plus
hydrochlorothiazide group; and LKþHCTZ, low Kþ diet plus
hydrochlorothiazide group.
a
c
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Figure 4 | Osteopontin expression of the ISOM of (a) NK, (b) LK,
(c) NKþHCTZ, and (d) LKþHCTZ rats. Increased renal tubular
osteopontin expression was demonstrated in the HCTZ-treated rats.
Original magnification  400. ISOM, inner stripe of outer medulla; NK,
normal Kþ diet group; LK, low Kþ diet group; NKþHCTZ, normal Kþ
diet plus hydrochlorothiazide group; and LKþHCTZ, low Kþ diet
plus hydrochlorothiazide group.
a b
c d
Figure 5 | PCNA expression of the ISOM of NK (a), LK (b),
NKþHCTZ (c) and LKþHCTZ (d) rats. Both NKþHCTZ and
LKþHCTZ rats showed more proliferative renal tubular cells of
collecting duct and mTAL compared with NK and LK rats. Original
magnification  400. ISOM, inner stripe of outer medulla; NK, normal
Kþ diet group; LK, low Kþ diet group; NKþHCTZ, normal Kþ diet
plus hydrochlorothiazide group; and LKþHCTZ, low Kþ diet plus
hydrochlorothiazide group.
Table 5 | Renal oxidative stress data
Group 1
(NK)
Group 2
(LK)
Group 3
(NK+HCTZ)
Group 4
(LK+HCTZ)
8-isoprostaglandin F2 alpha (ng g1 tissue)
Cortex 44.371.7 48.574.3 53.575.6y 50.872.3*
Medulla 74.875.2 74.273.2 72.874.7 70.071.0
Reduced glutathione (mmol g1 protein)
Cortex 2.7870.3 2.5070.4 2.5070.2 2.3570.3*
Medulla 4.0470.4 4.3070.6 4.0870.5 3.9970.4
LK, low K+ diet group; NK, normal K+ diet group; NK+HCTZ, normal K+ diet plus
hydrochlorothiazide group; LK+HCTZ, low K+ diet plus hydrochlorothiazide group.
*Po0.05, yPo0.01 vs group 1.
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Rats on a moderate LK diet with or without HCTZ
developed mild reduction (20–30%) of serum Kþ levels.
Importantly, hypokalemia was mild (3.2–3.6 mEq l1) and
similar to that observed commonly in patients. Furthermore,
the degree of hypokalemia was similar in rats receiving HCTZ
and a NK diet compared to rats treated with LK diet alone.
This allowed us to evaluate whether HCTZ has effects on
renal structure independent of hypokalemia.
Several features were common among the three groups
that developed hypokalemia. Notably, all three groups
developed endothelial dysfunction with impaired acetylcho-
line-dependent vasodilation (Figure 6a), and with reduced
serum, urinary, and renal nitrate/nitrites. These features
correlated with serum Kþ levels, which suggests that the
hypokalemia may have a role in these changes. Interestingly,
medullary NO levels were not altered, likely because the
medulla is a major site for neuronal NO synthase and
inducible NO synthase expression.24–28 All three groups also
developed mild proteinuria. Endothelial dysfunction is
known to be induced by hypokalemia,18 and both endothelial
dysfunction and proteinuria are known to be risk factors for
cardiovascular disease. These studies suggest that hypokale-
mia induced either by diet or thiazides could have long-term
negative cardiovascular effects.
Most interestingly, however, was the differential effect of
thiazides vs mild hypokalemia on renal structure. Thiazide-
treated rats with mild hypokalemia had subtle renal injury
that was not observed in the rats with diet induced mild
hypokalemia. This injury was characterized by focal glomer-
ular damage, which suggested glomerular ischemia or early
changes of glomerular atrophy, and was accompanied by
tubular injury primarily in the outer medullary area,
characterized by tubular osteopontin expression, tubular cell
proliferation, and increased macrophage infiltration. This
was accompanied by increased cortical oxidative stress and by
increased kidney weight adjusted for BW. Furthermore, these
changes were exacerbated when rats were placed on both a
LK diet and HCTZ.
There are several potential mechanisms to explain why
thiazides may cause renal injury greater than one would
expect for the level of hypokalemia. First, thiazides can
induce mild volume depletion, as suggested by the higher
hemoglobin and blood urea nitrogen values. The glomerular
injury also suggests the presence of chronic ischemia. The
observation that blood pressure was only slightly reduced
rules out hypotension as a cause and suggests that the
ischemic changes might be the result of impaired renal
autoregulation. One possibility is the combined effects of
volume depletion with arteriolar vasoconstriction from
reduced cortical NO and increased cortical oxidative stress,
8-isoprostaglandin F2 alpha, which is a potent preglomerular
vasoconstrictor.29 Consistent with the present observations,
previous studies involving spontaneously hypertensive rats
treated with HCTZ and NO blockade showed evidence of
glomerular injury and proteinuria.9 In addition, treatment
with a loop diuretic, furosemide, also reduced renal blood
flow and increased renal vascular resistance.30
Volume depletion from HCTZ may cause secondary
hyperaldosteronism as shown in previous studies31,32 and
in this study. Aldosterone may cause proteinuria and renal
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Figure 6 | (a) Percent relaxation of aortic rings in response to
acetylcholine. All hypokalemic rats (LK, NKþHCTZ, and LKþHCTZ)
had reduced endothelium-dependent vasorelaxation. (b) The positive
correlation between serum NO and percent aortic arch relaxation
(n¼ 12). Data are expressed as mean7s.d. NK, normal Kþ diet group;
LK, low Kþ diet group; NKþHCTZ, normal Kþ diet plus
hydrochlorothiazide group; and LKþHCTZ, low Kþ diet plus
hydrochlorothiazide group.
Table 6 | Effect of mild hypokalemia on nitric oxide levels
Group 1
(NK)
Group 2
(LK)
Group 3
(NK+HCTZ)
Group 4
(LK+HCTZ)
Serum nitrite (mM) 36.975.3 21.273.4y 22.676.1y 21.874.1y
Urine nitrate and
nitrite (nmol day1)
12117155 7647412* 7877317* 5337362y
Renal nitrate and nitrite (mmol g1 protein)
Cortex 1.5570.3 1.0670.2y 1.1570.2y 1.2570.2*
Medulla 1.3070.2 1.2570.2 1.5670.1 1.4070.5
NK, normal K+ diet group; LK, low K+ diet group; NK+HCTZ, normal K+ diet plus
hydrochlorothiazide group; LK+HCTZ, low K+ diet plus hydrochlorothiazide group.
*Po0.05, yPo0.01 vs group 1.
Table 7 | Correlation between serum NO, urine NO, serum K+,
and percent aortic ring relaxation in response to acetylcholine
Correlation; r (P-value) Serum K+ Serum NO Urine NO
Serum K+ — 0.69 (0.001) 0.64 (0.002)
Serum NO 0.69 (0.001) — 0.74 (o0.001)
% Aortic arch-ach relaxation 0.83 (0.001) 0.84 (0.001) 0.79 (0.002)
NO; nitric oxide; % aortic arch-ach relaxation.
The percent relaxation of aortic rings in response to acetylcholine.
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injury,33–35 and aldosterone blockade can ameliorate renal
injury in various experimental models.36–38 Aldosterone acts
in part by increasing plasminogen activator inhibitor-1
expression,39 which is increased in rats receiving HCTZ.40
HCTZ-treated rats also developed hyperglycemia, hyper-
triglyceridemia, and insulin resistance, which could poten-
tially cause or accelerate renal injury. Chronic hyperglycemia
can induce glomerular hypertrophy and mesangial matrix
expansion,41,42 but these were not observed in our rats
exposed to HCTZ. Therefore, the renal injury in the HCTZ
groups is likely not from hyperglycemia per se.
Thiazide use is also associated with the development of
hyperuricemia, which has been strongly linked with renal
hypertrophy, arteriolar vasoconstriction, and renal injury.43
However, we could not demonstrate differences in uric acid
levels in our groups. Uric acid levels can fluctuate during the
day, and it remains possible that levels could be different if
measured at other times (such as after drinking).
Urine volume of the HCTZ-treated rats was significantly
increased during the first 2 weeks. It has previously been
shown in humans that there is an association between higher
urine volume and faster decline in GFR.44 Ultimately, the
urine volume decline to baseline level might be explained by
the development of diuretic resistance. This resistance may be
caused by a decrease of renal blood flow and renal function.45
In conclusion, mild hypokalemia such as commonly
observed in clinical practice may be associated with
endothelial dysfunction and mild proteinuria, but we could
not document significant renal structural changes up to 20
weeks. In contrast, thiazides were associated not only with
hypokalemia, but also with hypomagnesemia, hyperlipide-
mia, impaired glucose metabolism, insulin resistance, and
aldosterone stimulation. Our study demonstrates another
side effect: the induction of mild renal injury that is greater
than expected for the degree of hypokalemia. Whether
similar concerns exist for loop diuretics that can also induce
similar metabolic abnormalities46 remains to be explored.
Importantly, diuretics may not be necessary in many patients
with chronic kidney disease. For example, in the Modifica-
tion of Diet in Renal Disease study and in the African
American Study of Kidney Disease and Hypertension trial,
about half of the patients achieved their blood pressure goals
without requirement of diuretic therapy.47 Further studies are
underway to determine the mechanism(s) by which thiazides
induce renal injury independent of potassium. Although
diuretic use can be life saving, physicians should monitor the
potential negative metabolic effects of thiazides and correct
them when they occur.
MATERIALS AND METHODS
All animal studies were approved by the University of Florida
Institutional Animal Use and Care Committee (IACUC).
Pilot study
Because of variable doses of HCTZ used in the other studies, for
example 3–80 mg kg1 day1,8,48,49 we performed pilot studies to
identify a dose of HCTZ that can cause mild hypokalemia. HCTZ
10 mg kg1 day1 in drinking water resulted in a modest natriuresis
(0.88 vs 0.17 mEq day1) and kaliuresis (1.9 vs 1.1 mEq day1,
P¼ 0.04) with a 20% reduction in serum Kþ after 8 weeks in rats on
a NK group (0.36%Kþ ) (from 4.6 to 3.7 mEq l1) and by 25% in
rats on a LK group (0.05%Kþ ) (from 4.7 to 3.6 mEq l1). This dose
of HCTZ reduced mean tail cuff systolic blood pressure from 136 to
127 mm Hg in the NK group and 133 to 128 mm Hg in the LK
group (P¼NS).
Experimental study
Male Sprague–Dawley rats (150–175 g, Charles River, Wilmington,
MA, USA) were placed on a NK (0.36%Kþ , 0.1%Naþ , Harlan,
Madison, WI, USA) for a 5-day run-in period and were divided into
four groups (n¼ 5–6 per group).
Group 1 (NK): normal Kþ diet
Group 2 (LK): low Kþ diet (0.05%Kþ , 0.1%Naþ , Harlan)
Group 3 (NKþHCTZ): normal Kþ diet plus HCTZ 10 mg kg1 day1
dissolved in drinking water
Group 4 (LKþHCTZ): low Kþ diet plus the same dose of HCTZ
Rats were weighed weekly and urine was collected over 18 h at
days 1, 3, 7, 14, and weeks 3, 4, 6, 10, 15, and 20. Serum was
collected at weeks 2, 4, 10, 15, and 20. Rats were killed at week 20.
Excised aortic artery (AA) segments (n¼ 3 per group) were used to
evaluate endothelium-dependent vasorelaxation. The cortex and
medulla of the right kidney was separated and frozen at 801C for
later analysis for nitrites and oxidative stress markers. The other
kidney was divided into cross-sectional pieces and fixed in Methyl
Carnoys, 10% formalin, and periodate lysine paraformaldehyde
fixative for histologic studies. Soleus muscle (40–80 mg) was
obtained for intracellular measurement of Kþ , Naþ , and Mgþ þ .
In the original protocol, blood pressure measurements were not
determined (other than in the pilot study noted above). We
therefore repeated the experiment using the same age and size
Sprague–Dawley rats with the same diets and dose of HCTZ (NK,
NKþHCTZ, LK, LKþHCTZ, n¼ 6 per group) and measured
systolic blood pressure by tail cuff sphygmomanometer (Visitech
BP2000, Visitech Systems, Apex, NC, USA) at week 6 as described
previously.50
Biochemical measurements
Serum and urine Kþ were determined by atomic absorption
spectrophotometer (Perkin-Elmer 306, Downers arove, IL, USA).
Blood chemistries were measured by an autoanalyzer (Alfa
Wassermann, West Caldwell, NJ, USA). Urinary protein was
measured with the protein kit (Bio-Rad, Hercules, CA, USA). A
complete blood count was done using the hematology analyzer
(Drew Scientific, Oxford, CT, USA).
Serum insulin and the quantitative insulin sensitivity check index
Fasting serum glucose and insulin were obtained at the week 15.
Serum insulin was determined by an enzyme-linked immunosor-
bent assay kit (Crystal Chem, Chicago, IL, USA). Quantitative
insulin sensitivity check index is equal to 1/(log[gluco-
se]þ log[insulin]), which predicts insulin sensitivity with lower
values representing more insulin resistance.51
Serum aldosterone measurement
Serum aldosterone was evaluated by an enzyme immunoassay kit
(Cayman Chemical, Ann Arbor, MI, USA).
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Determination of Kþ , Naþ , and Mgþ þ in soleus muscle
Soleus muscle was analyzed for Kþ , Naþ , and Mgþ þ as described
previously.52 Muscle tissue was electronically homogenized in 5%
TCA and centrifuged for 10 min at 1000 g. The supernatant was
diluted 1/10 with 15 mM Li2CO3 for Na
þ , Kþ , and with 0.5% Li2O3
for Mgþ þ measurements. All diluted samples were analyzed by an
atomic absorption spectrophotometer. The emission wavelength of
the sample and standard were read against blank at 766.5 nm for
Kþ , 589.0 nm for Naþ , and 285.2 nm wavelengths for Mgþ þ . The
protein concentration in the supernatants was measured using the
protein kit. Mgþ þ , Kþ , and Naþ contents of the muscles were
calculated and expressed as mmol per g wet tissue weight and mmol
per mg protein.
Renal histologic studies
Methyl Carnoys-fixed tissue (3-mm sections) was used for staining
with periodic acid-Schiff reagent, and hematoxylin–eosin. The
glomerular area and percentage of mesangial area per glomerulus
of 20 mid-cross section glomeruli for each rat were evaluated by an
Axioplan 2 imaging microscope (Carl Zeiss, Munich, Germany) and
Zeiss AutoMeasure software (Axiovision 4.1). The severity of
glomerular and tubulointerstitial injuries were determined blinded
and included glomerular sclerosis, mesangial matrix expansion,
glomerular ischemia, tubular cell vacuolization, tubular cell
hypertrophy and hyperplasia, tubular dilatation and cast formation,
tubular atrophy, interstitial cell infiltration, and fibrosis. For each
slide, at least 15–20 fields were graded for the extent of injury and
the mean score per biopsy was determined separately for the cortex
and outer medulla on a scale from 0–5, with grade 0¼ no injury,
1¼p10%, 2¼ 10–25%, 3¼ 25–50%, 4¼ 50–75%, and grade
5¼ 75–100% of the area determined.
Immunohistochemistry and quantification of staining
An indirect immunoperoxidase method was used to identify the
following antigens: osteopontin, a sensitive marker of tubulointer-
stitial injury,17 with a goat polyclonal antibody (OP199, gift of C
Giachelli, University of Washington, Seattle, WA, USA); macro-
phages with ED-1, a mouse monoclonal IgG1 (BD Pharmingen, San
Diego, CA, USA); and proliferating cells with mouse monoclonal
IgG antibody to PCNA (Sigma-Aldrich, St Louis, MO, USA).
To quantify the positive expression of osteopontin by injured
tubules, an Axioplan 2 imaging microscope and Zeiss AutoMeasure
software were used to determine the percent area occupied by
osteopontin-positive tubules at the cortex, and OSOM and ISOM
where 20 fields (1100 1400mm) of each area were measured at
 200 magnification. The mean percent area was calculated for each
biopsy. The number of macrophages (ED-1-positive cells per mm2)
and positive PCNA cells per mm2 in the entire cortex and medulla
were counted at  200 magnification and the average numbers were
calculated for each biopsy.
Renal 8-isoprostaglandin F 2 alpha, intracellular reduced
glutathione, and NO measurements
Measurements of renal oxidative stress and renal NO content were
determined. Briefly, the cortex and medulla were homogenized
separately at a weight/volume ratio of 1:6 with phosphate-buffered
saline and sonicated. 8-iso prostaglandin F2 alpha in homogenates
was measured by enzyme-linked immunosorbent assay (Cayman
Chemical) and expressed in ng per g wet tissue weight. To assess
intracellular-reduced glutathione and NO, the homogenate was
centrifuged at a high speed of 100 000 g. Supernatant was
ultrafiltrated using 10 000 Da filters. Intracellular-reduced glu-
tathione was measured as reported previously53 and expressed in
mmol per g protein. Total NO was measured with the colorimetric
assay kit (Cayman Chemical), which measures total nitrate and
nitrite concentrations (NO reaction products) and is expressed in
mmol per g protein. The tissue protein content of the supernatant
was determined by a BCA protein assay kit (Pierce, Rockford, IL,
USA).
Determination of vasorelaxation of aortic arch (AA) segments
Vasorelaxation of AA rings was performed as described previously.50
Briefly, the AA segments (1–1.5 mm diameter 3–4 mm length)
were isolated from each group of rats and suspended in individual
organ chambers (Radnoti Four-Unit Tissue Bath System). After 1 h
equilibration of resting force of 1.5 g, the vascular smooth muscle
cell or endothelium integrity of this AA segment was confirmed by
monitoring U-46619 (a thromboxane A2 mimetic, Sigma)-mediated
AA contraction or acetylcholine-mediated vasodilatation, respec-
tively. Stable contraction was induced by 0.5 mM U-46619 for 10 min
before acetylcholine (1 mM) was added to assess the endothelium-
dependent vasorelaxation response to agonist stimulating NO
production. The vascular tensions were continuously monitored
with an isometric force transducer (Harvard Apparatus, Holliston,
MA, USA). To standardize the data, a U-46619-induced stable
increase in vascular tone was set as 100%.
Measurement of serum and urinary NO
Serum and urine NO were measured as markers of NO bioavail-
ability,54 and endothelial dysfunction.55 Serum NO was determined
using the Sievers Nitric Oxide Analyzer (NOA280i; ozone-
chemiluminescence technology) as described previously.56 Urinary
NO was evaluated by using the nitrate/nitrite colorimetric assay kit
(Cayman Chemical).
Statistical analysis
All data are shown as mean7s.d. One-way analysis of variance
(SPSS 14.0) was used to determine the significance between the
mean of multiple groups. The paired and unpaired Student’s t-test
was used to compare the continuous variables of the specific two
groups. Pearson’s Correlation was used to address potential
associations. Statistical significance was defined as Po0.05.
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